2023
Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer
Hill B, Graf R, Shah K, Danziger N, Lin D, Quintanilha J, Li G, Haberberger J, Ross J, Santin A, Slomovitz B, Elvin J, Eskander R. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer. International Journal Of Gynecological Cancer 2023, 33: 504-513. PMID: 36750267, PMCID: PMC10086481, DOI: 10.1136/ijgc-2022-004026.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAdvanced endometrial cancerTumor mutational burdenAdjusted hazard ratioEndometrial cancerCheckpoint inhibitorsOverall survivalMismatch repair deficiencyFrontline treatmentMicrosatellite instabilityMutational burdenNext treatmentTreatment discontinuationSingle-agent immune checkpoint inhibitorsAdvanced stage endometrial cancerImmune checkpoint inhibitor effectivenessImmune checkpoint inhibitor monotherapyImmune checkpoint inhibitor treatmentCox proportional hazards modelCheckpoint inhibitor monotherapyStage endometrial cancerPhase III trialsRepair deficiencyCheckpoint inhibitor treatmentLog-rank test
2022
Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study.
Santin A, Graf R, Shah K, Kelly A, Danziger N, Lin D, Oxnard G, Elvin J. Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study. Journal Of Clinical Oncology 2022, 40: 5596-5596. DOI: 10.1200/jco.2022.40.16_suppl.5596.Peer-Reviewed Original ResearchSingle-agent immune checkpoint inhibitorsImmune checkpoint inhibitorsTumor mutational burdenCheckpoint inhibitorsMEC patientsChemotherapy effectivenessMSI statusAnti-PD1 immune checkpoint inhibitorsFirst-line immune checkpoint inhibitorsMultivariable Cox proportional hazards modelsCox proportional hazards modelMetastatic endometrial carcinomaOverall survival comparisonEndometrial carcinoma patientsMut/MbProportional hazards modelReal-world studyPrespecified analysis planHazard ratioStandard chemotherapyCarcinoma patientsEndometrial carcinomaPredictive biomarkersChemotherapy treatmentFavorable outcome